Andrea Malfettone
Overview
Explore the profile of Andrea Malfettone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Lopez-Miranda E, Gion M, Abad E, et al.
Front Oncol
. 2023 Jul;
13:1048242.
PMID: 37496662
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate...
2.
Perez-Garcia J, Gebhart G, Borrego M, Schmid P, Marme F, Prat A, et al.
Future Oncol
. 2022 Oct;
18(33):3677-3688.
PMID: 36300423
What Is This Summary About?: This is a summary of a publication about the PHERGain study, which was published in in May 2021. The study includes 376 women with a...
3.
Di Cosimo S, Perez-Garcia J, Bellet M, Dalenc F, Gil Gil M, Borrego M, et al.
Oncologist
. 2022 Oct;
28(1):23-32.
PMID: 36239405
Background: Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Despite its manageable toxicity profile, venous...
4.
Albanell J, Perez-Garcia J, Gil-Gil M, Curigliano G, Ruiz-Borrego M, Comerma L, et al.
Clin Cancer Res
. 2022 Sep;
29(1):67-80.
PMID: 36165912
Purpose: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer...
5.
Sanchez-Conde M, Vizcarra P, Perez-Garcia J, Gion M, Martialay M, Taboada J, et al.
Int J Infect Dis
. 2022 Aug;
123:97-103.
PMID: 35987472
Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor...
6.
Carles J, Alonso-Gordoa T, Mellado B, Mendez-Vidal M, Vazquez S, Gonzalez-Del-Alba A, et al.
Eur J Cancer
. 2022 Aug;
173:317-326.
PMID: 35981452
Purpose: The paper aims to evaluate the efficacy and safety of Ra in patients who progressed after first-line androgen deprivation therapy. Patients And Methods: EXCAAPE (NCT03002220) was a multicentre, single-arm,...
7.
Perez-Garcia J, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo J, de la Haba-Rodriguez J, et al.
Neuro Oncol
. 2022 May;
25(1):157-166.
PMID: 35639825
Background: Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active...
8.
Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J, et al.
JCO Precis Oncol
. 2022 Jan;
5:93-102.
PMID: 34994593
Purpose: Treatment guidelines for advanced non-small-cell lung cancer (aNSCLC) recommend broad molecular profiling for targeted therapy selection. This study prospectively assessed comprehensive next-generation sequencing (NGS) of cell-free circulating tumor DNA...
9.
Gion M, Perez-Garcia J, Llombart-Cussac A, Sampayo-Cordero M, Cortes J, Malfettone A
Ther Adv Med Oncol
. 2021 Dec;
13:17588359211059587.
PMID: 34868353
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in...
10.
Majem M, Sullivan I, Viteri S, Lopez-Vivanco G, Cobo M, Sanchez J, et al.
Eur J Cancer
. 2021 Nov;
159:174-181.
PMID: 34763195
Aim Of The Study: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer (NSCLC)...